Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial-Reference-Cited by-同舟云学术

Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial

Published:2019-12 Issue:12 Volume:20 Page:1702-1709
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Ceresoli Giovanni L,Aerts Joachim G,Dziadziuszko Rafal,Ramlau Rodryg,Cedres Susana,van Meerbeeck Jan P,Mencoboni Manlio,Planchard David,Chella Antonio,Crinò Lucio,Krzakowski Maciej,Rüssel Jörn,Maconi Antonio,Gianoncelli Letizia,Grosso Federica

Funder

Fondazione Buzzi Unicem

Publisher

Elsevier BV

Subject

Oncology

Reference27 articles.

1. Malignant mesothelioma;Robinson;Lancet,2005

2. Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008;Delgermaa;Bull World Health Organ,2011

3. Randomized Phase III Study of Cisplatin With or Without Raltitrexed in Patients With Malignant Pleural Mesothelioma: An Intergroup Study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada

4. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma;Vogelzang;J Clin Oncol,2003

5. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma;Ceresoli;J Clin Oncol,2006

Cited by 105 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Malignant pleural mesothelioma: The disdained member of thoracic oncology!;World Journal of Experimental Medicine;2024-09-20

2. New Treatment for Pleural Mesothelioma;Haigan;2024-08-20

3. Alternating electric fields transform the intricate network of tumour vasculature into orderly parallel capillaries and enhance the anti‐angiogenesis effect of bevacizumab;Cell Proliferation;2024-08-19

4. Long-Term Survival in Hepatocellular Carcinoma following Second-Line Tumor Treating Fields Therapy and Sorafenib: A Case Report;Case Reports in Oncology;2024-07-31

5. Global post‑marketing safety surveillance of Tumor Treating Fields (TTFields) therapy in over 25,000 patients with CNS malignancies treated between 2011–2022;Journal of Neuro-Oncology;2024-06-29